
Today on Drug Discovery & Development
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
More than a decade ago, the American Society of Clinical Oncology (ASCO) launched CancerLinQ, a platform designed to pool electronic health record data from oncology practices, turning routine patient encounters into a learning system. The platform has since become central to ConcertAI, an oncology-focused AI and real-world data company, which acquired it from ASCO in…Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, Moderna signalled a strategic expansion beyond its established vaccine and rare disease franchises, unveiling new programs in in vivo CAR-T and solid tumor oncology. The firm also revealed an AI-driven research platform it says will accelerate the pace of drug discovery across its pipeline. The company publicly revealed two…Drug Discovery and Development See More >

CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
Thermo Fisher’s Patheon division has signed an exclusive agreement with AustinPx to install the Texas CDMO’s KinetiSol technology at Patheon’s Bend, Oregon, and Cincinnati sites. AustinPx specializes in bioavailability enhancement for orally delivered small molecules, and the placement plugs into Patheon’s Quadrant 2 platform, which applies AI/ML to formulation prediction. It expands access to KinetiSol-enabled…

Top pharma companies set sustainability goals, but emissions are still increasing

SLAS 2026: Orchestration patforms, API-first instruments and the rise of semiautonomous labs

How digital tools and AI are accelerating drug discovery

Pharma 2035 Playbook: Speed, focus and conviction in an uncertain world
Sponsored Content See More >
Genomics/Proteomics See More >

Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification

Spatial biology: Transforming our understanding of cellular environments

Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials

Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
Infectious Disease See More >

FDA refuses to review Moderna’s mRNA flu vaccine
Moderna received a refusal-to-file (RTF) letter from the FDA’s Center for Biologics Evaluation and Research (CBER) for its investigational mRNA vaccine for influenza, the company said Tuesday. The letter is inconsistent with the feedback received at pre-Phase 3 and pre-submission consultations, Moderna said. The company has requested a meeting with the FDA. The vaccine, mRNA-1010,…
Oncology See More >

How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
More than a decade ago, the American Society of Clinical Oncology (ASCO) launched CancerLinQ, a platform designed to pool electronic health record data from oncology practices, turning routine patient encounters into a learning system. The platform has since become central to ConcertAI, an oncology-focused AI and real-world data company, which acquired it from ASCO in…

Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform

Calderasib’s real innovation: designed for combinability and potency

Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026




























